查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790280

照护现场诊断分子诊断市场规模、份额和趋势分析报告：按应用、技术、测试地点、最终用途、地区和细分市场预测，2025 年至 2033 年

Point Of Care Molecular Diagnostics Market Size, Share & Trends Analysis Report By Application (Infectious Diseases, Oncology, Prenatal Testing, Endocrinology), By Technology, By Test Location, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

照护现场分子诊断市场概况

预计2024年全球照护现场诊断市场规模将达82.2亿美元，2033年将达到144.7亿美元，2025年至2033年的复合年增长率为6.52%。该市场专注于在患者附近进行快速且准确的分子检测，以便及时做出临床决策。这些平台的应用范围广泛，包括感染疾病检测、呼吸系统疾病和性行为感染传染病等。

市场成长的动力源于对分散式检查日益增长的需求，尤其是在资源有限和重症监护环境中。日益加重的感染疾病负担以及对快速週转时间的需求，推动了照护现场技术的广泛应用。微流体、等温扩增和携带式PCR系统等技术进步正在提高这些诊断方法的准确性和易用性。此外，快速反应检测作为疫情后医疗保健重点日益受到重视，这也进一步推动了市场扩张。

此外，基层医疗机构中的即时分子诊断涵盖从简单的血糖检测到复杂的血液凝固检验等各种检测。在一些诊所，专家已从传统的实验室检测转向即时检测，从而避免了检体製备和运输过程中的延误，从而有助于缩短确定是否需要进一步检测的时间。即时分子诊断的其他优点包括更快获得结果、更低的成本和更好的疗效。近年来，即时分子诊断产业发展迅速，尤其是在美国和欧洲国家，这得益于人们对各种问题的认识不断提高，包括即时检测的医疗和组织挑战以及经济效益。

老龄化受到多种环境和遗传因素交互作用的影响，被认为是癌症发展的最重要风险因素。根据美国国家癌症研究所的监测、流行病学和最终结果 (SEER)资料库，估计有 38% 的女性和 43% 的男性在其一生中会罹患癌症。近三分之二的新癌症病例是在 65 岁或以上的人群中诊断出来的，这表明老龄化增长会导致癌症的可能性增加。分子诊断起着至关重要的作用，因为它对癌症、感染疾病和心血管疾病的管理有显着的影响。因此，它对于公共卫生监测和检测至关重要。因此，老年人口的增加预计将推动市场成长。

此外，市场相关人员正在不断开发新的即时检测产品，以抓住市场机会。例如，2023年2月，Huwel Lifesciences设计了一款用于病毒分型的可携式RT-PCR设备。该公司声称，该检测大约需要30分钟，可用于透过血液或胃肠道样本检测感染疾病和其他感染疾病。此外，2023年4月，Curative, Inc.宣布分拆Sensible Diagnostics，专注于商业化一款新的即时检测PCR平台，该平台可在10分钟内提供高精度结果。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
  • 市场驱动因素
    • 对快速和分散检测的需求不断增长
    • 感染疾病率上升
    • 分子平台的技术进步
  • 市场限制因素分析
    • 分子 POC 设备和耗材高成本
    • 监管和品质保证挑战
  • 商业环境分析
    • 依因素（政治/法律、经济/技术）进行 SWOT 分析
    • 波特五力分析
    • COVID-19影响分析

第四章 技术业务分析

  • 照护现场分子诊断市场：技术变革分析
  • 基于PCR
    • 2021-2033年市场
  • 依基因序列
    • 2021-2033年市场
  • 杂交基地
    • 2021-2033年市场
  • 基于微阵列
    • 2021-2033年市场

第五章：应用业务分析

  • 照护现场分子诊断市场：应用差异分析
  • 感染疾病
    • 感染疾病市场，2021-2033年
    • HIV POC
    • 困难梭状芽孢桿菌POC
    • HBV POC
    • 肺炎或链球菌感染疾病
    • 呼吸道融合细胞病毒(RSV) 临床验证
    • HPV POC
    • 流感/流感 POC
    • HCV POC
    • MRSA POC
    • 结核病和抗药性结核病的即时治疗
    • HSV POC
    • 其他感染疾病
  • 肿瘤学
    • 2021-2033年市场
  • 血液学
    • 2021-2033年市场
  • 产前检查
    • 2021-2033年市场
  • 内分泌学
    • 2021-2033年市场
  • 其他的
    • 2021-2033年市场

第六章 测试地点业务分析

  • 照护现场分子诊断市场：侦测地点差异分析
  • OTC
    • 2021-2033年市场
  • POC
    • 2021-2033年市场

第七章最终用途业务分析

  • 照护现场分子诊断市场：最终用途变异分析
  • 分散式实验室
    • 2021-2033年市场
  • 医院
    • 2021-2033年市场
  • 居家医疗
    • 2021-2033年市场
  • 辅助医疗设施
    • 2021-2033年市场
  • 其他的
    • 2021-2033年市场

第八章区域业务分析

  • 2024 年及 2033 年 POC 分子诊断市场占有率（按地区）
  • 北美洲
    • 2021-2033年北美照护现场分子诊断市场
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2021-2033年欧洲照护现场分子诊断市场
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2021-2033年亚太地区照护现场分子诊断市场
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2021-2033年拉丁美洲照护现场分子诊断市场
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 2021-2033 年中东和非洲照护现场分子诊断市场
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 参与企业概况
  • 参与企业
    • 市场领导者
    • 照护现场分子诊断市场占有率分析（2023年）
    • 公司简介
    • 战略地图
Product Code: 978-1-68038-886-2

Point-of-Care Molecular Diagnostics Market Summary

The global point of care molecular diagnostics market size was estimated at USD 8.22 billion in 2024 and is projected to reach USD 14.47 billion by 2033, growing at a CAGR of 6.52% from 2025 to 2033. This market focuses on rapid and accurate molecular testing conducted near the patient, enabling timely clinical decision-making. These platforms are used across various applications, particularly in infectious disease detection, respiratory illnesses, and sexually transmitted infections.

Market growth is driven by the rising demand for decentralized testing, especially in resource-limited settings and emergency care environments. The increasing burden of infectious diseases and the need for rapid turnaround time have expanded the adoption of point-of-care molecular technologies. Technological advances in microfluidics, isothermal amplification, and portable PCR systems are enhancing the accuracy and usability of these diagnostics. In addition, post-pandemic healthcare priorities emphasize rapid response testing, further supporting market expansion.

Moreover, POC molecular diagnostics in primary care settings range from simple glucose testing to complex coagulation testing. In several clinics, professionals are switching to POC testing from conventional lab testing, which helps shorten the time taken to decide whether further tests are required by avoiding delays during specimen preparation and transport. Other advantages of POC molecular diagnostics are rapid availability of results, lower costs, and better outcomes. The point of care molecular diagnostics industry has grown rapidly in the past few years, especially in the U.S. and European countries, owing to increased awareness regarding various issues such as medical & organizational concerns and economic advantages of POCT.

Aging is influenced by the interaction of several environmental and genetic factors and is characterized as the single most substantial risk factor for cancer development. Based on the U.S. National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Database, 38% of women and 43% of men are estimated to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are diagnosed in people aged 65 and above, which highlights that aging can make people more vulnerable to cancer. This is where molecular diagnostics play an important role, as it has a tremendous impact on the management of cancer, infectious diseases, and cardiovascular diseases. It is, therefore, vital for public health surveillance and detection. Thus, the growing geriatric population is expected to drive market growth.

Moreover, market players are continuously involved in the development of novel POC testing products to capitalize on market opportunities. For instance, in February 2023, Huwel Lifesciences designed a portable RT-PCR machine to test types of viruses. The company claimed that the test takes around 30 minutes and can be used to detect respiratory and other infections using blood and gastrointestinal samples. Moreover, in April 2023, Curative, Inc. announced the spin-off of Sensible Diagnostics, focusing on the commercialization of a novel POC PCR testing platform to provide results within 10 minutes with high accuracy.

Global Point Of Care Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global point of care molecular diagnostics market report based on application, technology, test location, end-use, and region:

  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • PCR-based
  • Genetic Sequencing-based
  • Hybridization-based
  • Microarray-based
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Infectious Diseases
    • HIV POC
    • Clostridium difficile POC
    • HBV POC
    • Pneumonia or Streptococcus associated infections
    • Respiratory syncytial virus (RSV) POC
    • HPV POC
    • Influenza/Flu POC
    • HCV POC
    • MRSA POC
    • TB and drug-resistant TB POC
    • HSV POC
    • Other Infectious Diseases
  • Oncology
  • Hematology
  • Prenatal Testing
  • Endocrinology
  • Other Applications
  • Test Location Outlook (Revenue, USD Million, 2021 - 2033)
  • OTC
  • POC
  • End-use Outlook (Revenue, USD Million, 2021 - 2033)
  • Decentralized Labs
  • Hospitals
  • Home-care
  • Assisted Living Healthcare Facilities
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Growing Demand for Rapid and Decentralized Testing
    • 3.4.2. Rising Prevalence of Infectious Diseases
    • 3.4.3. Technological Advancements in Molecular Platforms
  • 3.5. Market Restraint Analysis
    • 3.5.1. High Cost of Molecular POC Devices and Consumables
    • 3.5.2. Regulatory and Quality Assurance Challenges
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Technology Business Analysis

  • 4.1. Point-of-Care Molecular Diagnostics Market: Technology Movement Analysis
  • 4.2. PCR-based
    • 4.2.1. PCR-based Market, 2021 - 2033 (USD Million)
  • 4.3. Genetic Sequencing-based
    • 4.3.1. Genetic Sequencing-based Market, 2021 - 2033 (USD Million)
  • 4.4. Hybridization-based
    • 4.4.1. Hybridization-based Market, 2021 - 2033 (USD Million)
  • 4.5. Microarray-based
    • 4.5.1. Microarray-based Market, 2021 - 2033 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Point-of-Care Molecular Diagnostics Market: Application Movement Analysis
  • 5.2. Infectious Diseases
    • 5.2.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
    • 5.2.2. HIV POC
      • 5.2.2.1. HIV POC Market, 2021 - 2033 (USD Million)
    • 5.2.3. Clostridium difficile POC
      • 5.2.3.1. Clostridium difficile POC Market, 2021 - 2033 (USD Million)
    • 5.2.4. HBV POC
      • 5.2.4.1. HBV POC Market, 2021 - 2033 (USD Million)
    • 5.2.5. Pneumonia or Streptococcus associated infections
      • 5.2.5.1. Pneumonia or Streptococcus associated infections Market, 2021 - 2033 (USD Million)
    • 5.2.6. Respiratory Syncytial Virus (RSV) POC
      • 5.2.6.1. Respiratory Syncytial Virus (RSV) POC Market, 2021 - 2033 (USD Million)
    • 5.2.7. HPV POC
      • 5.2.7.1. HPV POC Market, 2021 - 2033 (USD Million)
    • 5.2.8. Influenza/Flu POC
      • 5.2.8.1. Influenza/Flu POC Market, 2021 - 2033 (USD Million)
    • 5.2.9. HCV POC
      • 5.2.9.1. HCV POC Market, 2021 - 2033 (USD Million)
    • 5.2.10. MRSA POC
      • 5.2.10.1. MRSA POC Market, 2021 - 2033 (USD Million)
    • 5.2.11. TB and drug-resistant TB POC
      • 5.2.11.1. TB and drug-resistant TB POC Market, 2021 - 2033 (USD Million)
    • 5.2.12. HSV POC
      • 5.2.12.1. HSV POC Market, 2021 - 2033 (USD Million)
    • 5.2.13. Other Infectious Diseases
      • 5.2.13.1. Other Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 5.3. Oncology
    • 5.3.1. Oncology Market, 2021 - 2033 (USD Million)
  • 5.4. Hematology
    • 5.4.1. Hematology Market, 2021 - 2033 (USD Million)
  • 5.5. Prenatal Testing
    • 5.5.1. Prenatal Testing Market, 2021 - 2033 (USD Million)
  • 5.6. Endocrinology
    • 5.6.1. Endocrinology Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Test Location Business Analysis

  • 6.1. Point-of-Care Molecular Diagnostics Market: Test Location Movement Analysis
  • 6.2. OTC
    • 6.2.1. OTC Market, 2021 - 2033 (USD Million)
  • 6.3. POC
    • 6.3.1. POC Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Point-of-Care Molecular Diagnostics Market: End Use Movement Analysis
  • 7.2. Decentralized Labs
    • 7.2.1. Decentralized Labs Market, 2021 - 2033 (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 7.4. Homecare
    • 7.4.1. Home-care Market, 2021 - 2033 (USD Million)
  • 7.5. Assisted Living Healthcare Facilities
    • 7.5.1. Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Point-of-Care Molecular Diagnostics Market Share By Region, 2024 & 2033
  • 8.2. North America
    • 8.2.1. North America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Target Disease Prevalence
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. Regulatory Framework
      • 8.2.2.5. Reimbursement Scenario
      • 8.2.2.6. U.S. Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD MILLION)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. Reimbursement Scenario
      • 8.2.3.6. Canada Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.2.4. Mexico
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Reimbursement Scenario
      • 8.2.4.6. Mexico Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.2. Germany
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Target Disease Prevalence
      • 8.3.2.3. Competitive Scenario
      • 8.3.2.4. Regulatory Framework
      • 8.3.2.5. Reimbursement Scenario
      • 8.3.2.6. Germany Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. Reimbursement Scenario
      • 8.3.3.6. UK Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Reimbursement Scenario
      • 8.3.4.6. France Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. Reimbursement Scenario
      • 8.3.5.6. Italy Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Reimbursement Scenario
      • 8.3.6.6. Spain Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Reimbursement Scenario
      • 8.3.7.6. Denmark Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Reimbursement Scenario
      • 8.3.8.6. Sweden Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Reimbursement Scenario
      • 8.3.9.6. Norway Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Competitive Scenario
      • 8.4.2.4. Regulatory Framework
      • 8.4.2.5. Reimbursement Scenario
      • 8.4.2.6. Japan Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Reimbursement Scenario
      • 8.4.3.6. China Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. Reimbursement Scenario
      • 8.4.4.6. India Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.5. South Korea
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. Reimbursement Scenario
      • 8.4.5.6. South Korea Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Reimbursement Scenario
      • 8.4.6.6. Australia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Reimbursement Scenario
      • 8.4.7.6. Thailand Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Competitive Scenario
      • 8.5.2.4. Regulatory Framework
      • 8.5.2.5. Reimbursement Scenario
      • 8.5.2.6. Brazil Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.5.3. Argentina
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Reimbursement Scenario
      • 8.5.3.6. Argentina Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Competitive Scenario
      • 8.6.2.4. Regulatory Framework
      • 8.6.2.5. Reimbursement Scenario
      • 8.6.2.6. South Africa Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. Reimbursement Scenario
      • 8.6.3.6. Saudi Arabia Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Reimbursement Scenario
      • 8.6.4.6. UAE Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. Reimbursement Scenario
      • 8.6.5.6. Kuwait Point-of-Care Molecular Diagnostics market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant's overview
  • 9.2. Financial performance
  • 9.3. Participant categorization
    • 9.3.1. Market Leaders
    • 9.3.2. Point-of-Care Molecular Diagnostics Market Share Analysis, 2023
    • 9.3.3. Company Profiles
      • 9.3.3.1. Abbott
        • 9.3.3.1.1. Company Overview
        • 9.3.3.1.2. Financial Performance
        • 9.3.3.1.3. Product Benchmarking
        • 9.3.3.1.4. Strategic Initiatives
      • 9.3.3.2. Bayer AG
        • 9.3.3.2.1. Company Overview
        • 9.3.3.2.2. Financial Performance
        • 9.3.3.2.3. Product Benchmarking
        • 9.3.3.2.4. Strategic Initiatives
      • 9.3.3.3. F. Hoffmann-La Roche AG
        • 9.3.3.3.1. Company Overview
        • 9.3.3.3.2. Financial Performance
        • 9.3.3.3.3. Product Benchmarking
        • 9.3.3.3.4. Strategic Initiatives
      • 9.3.3.4. Nova Biomedical
        • 9.3.3.4.1. Company Overview
        • 9.3.3.4.2. Financial Performance
        • 9.3.3.4.3. Product Benchmarking
        • 9.3.3.4.4. Strategic Initiatives
      • 9.3.3.5. QIAGEN
        • 9.3.3.5.1. Company Overview
        • 9.3.3.5.2. Financial Performance
        • 9.3.3.5.3. Product Benchmarking
        • 9.3.3.5.4. Strategic Initiatives
      • 9.3.3.6. Nipro Diagnostics
        • 9.3.3.6.1. Company Overview
        • 9.3.3.6.2. Financial Performance
        • 9.3.3.6.3. Product Benchmarking
        • 9.3.3.6.4. Strategic Initiatives
      • 9.3.3.7. Danaher
        • 9.3.3.7.1. Company Overview
        • 9.3.3.7.2. Financial Performance
        • 9.3.3.7.3. Product Benchmarking
        • 9.3.3.7.4. Strategic Initiatives
      • 9.3.3.8. Bio-Rad Laboratories, Inc.
        • 9.3.3.8.1. Company Overview
        • 9.3.3.8.2. Financial Performance
        • 9.3.3.8.3. Product Benchmarking
        • 9.3.3.8.4. Strategic Initiatives
      • 9.3.3.9. bioMerieux
        • 9.3.3.9.1. Company Overview
        • 9.3.3.9.2. Financial Performance
        • 9.3.3.9.3. Product Benchmarking
        • 9.3.3.9.4. Strategic Initiatives
      • 9.3.3.10. Agilent Technologies, Inc.
        • 9.3.3.10.1. Company Overview
        • 9.3.3.10.2. Financial Performance
        • 9.3.3.10.3. Product Benchmarking
        • 9.3.3.10.4. Strategic Initiatives
      • 9.3.3.11. Abaxis
        • 9.3.3.11.1. Company Overview
        • 9.3.3.11.2. Financial Performance
        • 9.3.3.11.3. Product Benchmarking
        • 9.3.3.11.4. Strategic Initiatives
      • 9.3.3.12. OraSure Technologies
        • 9.3.3.12.1. Company Overview
        • 9.3.3.12.2. Financial Performance
        • 9.3.3.12.3. Product Benchmarking
        • 9.3.3.12.4. Strategic Initiatives
    • 9.3.4. Strategy Mapping
      • 9.3.4.1. Expansion
      • 9.3.4.2. Acquisition
      • 9.3.4.3. Collaborations
      • 9.3.4.4. Disease Type/Drug Class Launch
      • 9.3.4.5. Partnerships
      • 9.3.4.6. Others

List of Tables

  • Table 1. Point-of-care Molecular Diagnostics Market - Industry Snapshot & Key Buying Criteria, 2021 - 2033
  • Table 2. Global Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 3. Global Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 4. Global Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 5. Global Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 6. Global Point-of-care Molecular Diagnostics Market, by region, 2021 - 2033 (USD Million)
  • Table 7. Point-of-care Molecular Diagnostics- Key market driver analysis
  • Table 8. Point-of-care Molecular Diagnostics- Key market restraint analysis
  • Table 9. North America Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 10. North America Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 11. North America Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 12. North America Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 13. North America Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 14. U.S. Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 15. U.S. Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 16. U.S. Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 17. U.S. Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 18. Canada Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 19. Canada Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 20. Canada Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 21. Canada Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 22. Mexico Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 23. Mexico Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 24. Mexico Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 25. Mexico Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 26. Europe Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 27. Europe Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 28. Europe Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 29. Europe Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 30. Europe Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 31. Germany Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 32. Germany Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 33. Germany Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 34. Germany Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 35. UK Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 36. UK Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 37. UK Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 38. UK Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 39. France Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 40. France Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 41. France Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 42. France Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 43. Italy Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 44. Italy Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 45. Italy Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 46. Italy Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 47. Spain Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 48. Spain Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 49. Spain Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 50. Spain Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 51. Denmark Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 52. Denmark Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 53. Denmark Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 54. Denmark Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 55. Sweden Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 56. Sweden Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 57. Sweden Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 58. Sweden Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 59. Norway Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 60. Norway Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 61. Norway Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 62. Norway Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 63. Asia Pacific Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 64. Asia Pacific Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 65. Asia Pacific Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 66. Asia Pacific Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 67. Asia Pacific Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 68. Japan Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 69. Japan Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 70. Japan Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 71. Japan Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 72. China Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 73. China Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 74. China Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 75. China Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 76. India Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 77. India Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 78. India Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 79. India Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 80. Australia Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 81. Australia Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 82. Australia Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 83. Australia Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 84. South Korea Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 85. South Korea Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 86. South Korea Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 87. South Korea Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 88. Thailand Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 89. Thailand Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 90. Thailand Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 91. Thailand Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 92. Latin America Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 93. Latin America Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 94. Latin America Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 95. Latin America Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 96. Latin America Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 97. Brazil Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 98. Brazil Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 99. Brazil Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 100. Brazil Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 101. Argentina Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 102. Argentina Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 103. Argentina Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 104. Argentina Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 105. MEA Point-of-care Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
  • Table 106. MEA Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 107. MEA Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 108. MEA Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 109. MEA Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 110. South Africa Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 111. South Africa Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 112. South Africa Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 113. South Africa Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 114. Saudi Arabia Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 115. Saudi Arabia Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 116. Saudi Arabia Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 117. Saudi Arabia Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 118. UAE Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 119. UAE Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 120. UAE Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 121. UAE Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)
  • Table 122. Kuwait Point-of-care Molecular Diagnostics Market, by application, 2021 - 2033 (USD Million)
  • Table 123. Kuwait Point-of-care Molecular Diagnostics Market, by technology, 2021 - 2033 (USD Million)
  • Table 124. Kuwait Point-of-care Molecular Diagnostics Market, by test location, 2021 - 2033 (USD Million)
  • Table 125. Kuwait Point-of-care Molecular Diagnostics Market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Point-Of-Care Molecular Diagnostics Market Segmentation
  • Fig. 2 Global Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 3 Point-Of-Care Molecular Diagnostics Market Dynamics
  • Fig. 4 Key Opportunities Prioritized, 2018
  • Fig. 5 Point-Of-Care Molecular Diagnostics Market - Porter's Analysis
  • Fig. 6 Point-Of-Care Molecular Diagnostics Market - PESTEL Analysis
  • Fig. 7 Point-Of-Care Molecular Diagnostics Revenue Share, By Application, 2024 & 2033
  • Fig. 8 POC Mdx Infectious Diseases Market, 2021 - 2033 (USD Million)
  • Fig. 9 POC Mdx Oncology Market, 2021 - 2033 (USD Million)
  • Fig. 10 POC Mdx Hematology Market, 2021 - 2033 (USD Million)
  • Fig. 11 POC Mdx Prenatal Testing Market, 2021 - 2033 (USD Million)
  • Fig. 12 POC Mdx Endocrinology Market, 2021 - 2033 (USD Million)
  • Fig. 13 POC Mdx Other Applications Market, 2021 - 2033 (USD Million)
  • Fig. 14 Point-Of-Care Molecular Diagnostics Revenue Share, By Technology, 2024 & 2033
  • Fig. 15 POC Mdx PCR-Based Market, 2021 - 2033 (USD Million)
  • Fig. 16 POC Mdx Genetic Sequencing-Based Market, 2021 - 2033 (USD Million)
  • Fig. 17 POC Mdx Hybridization-Based Market, 2021 - 2033 (USD Million)
  • Fig. 18 POC Mdx Microarray-Based Market, 2021 - 2033 (USD Million)
  • Fig. 19 Point-Of-Care Molecular Diagnostics Revenue Share, By Test Location, 2024 & 2033
  • Fig. 20 POC Mdx Over-The-Counter Market, 2021 - 2033 (USD Million)
  • Fig. 21 POC Mdx Point-Of-Care Market, 2021 - 2033 (USD Million)
  • Fig. 22 Point-Of-Care Molecular Diagnostics Revenue Share, By End Use, 2024 & 2033
  • Fig. 23 POC Mdx Decentralized Labs Market, 2021 - 2033 (USD Million)
  • Fig. 24 POC Mdx Hospitals Market, 2021 - 2033 (USD Million)
  • Fig. 25 POC Mdx Home-Care Market, 2021 - 2033 (USD Million)
  • Fig. 26 POC Mdx Assisted Living Healthcare Facilities Market, 2021 - 2033 (USD Million)
  • Fig. 27 POC Mdx Other Uses Market, 2021 - 2033 (USD Million)
  • Fig. 28 Point-Of-Care Molecular Diagnostics Revenue Share, By Test Location, 2024 & 2033
  • Fig. 29 POC Mdx OTC Market, 2021 - 2033 (USD Million)
  • Fig. 30 POC Mdx POC Market, 2021 - 2033 (USD Million)
  • Fig. 31 Point-Of-Care Molecular Diagnostics Revenue Share, By Region, 2024 & 2033
  • Fig. 32 North America Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 33 US Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 36 Europe Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 37 Germany Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 38 UK Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 39 France Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 41 Spain Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 42 Denmark Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 43 Sweden Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 45 Asia Pacific Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 46 Japan Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 47 China Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 48 India Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 49 Australia Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 50 South Korea Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 51 Thailand Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 52 Latin America Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 53 Brazil Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 54 Argentina Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 55 MEA Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 56 South Africa Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 57 Saudi Arabia Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 58 UAE Point-Of-Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 59 Kuwait Point-Of-Care Molecular Diagnostics Market, 2021 - 2033(USD Million)